BRAF and Langerhans cell histiocytosis: All BRAF-mutated patients had symptoms requiring treatment ranging from non-steroidal inflammatory agents (n = 1) for LCH and from conventional therapies (n = 6) to targeted therapies (n = 4) for severe cases.